V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Maravai Lifesciences Holdings Executive Compensation (FY25)

MRVI · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Bernd Brust
Median of the other named officers
$1,790,271
6 officers, excluding the chief executive
Latest say-on-pay support
=
May 26, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Maravai Lifesciences Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 21, 2026Latest filing (8-K): May 29, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Maravai Lifesciences Holdings brief$1,500Get the executive brief
Velarion Member, one year
289 figures on this page: 285 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: William Martin → Bernd Brust
Say-on-pay support: 80.9% → 98.6% (17.7 points higher)
CEO pay ratio: 48.1:1 → 93:1 (93.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Maravai Lifesciences Holdings' chief executive and what were they paid?
Total compensation for Bernd Brust, Chief Executive Officer, came to $10,129,708 in fiscal 2025.
What was Maravai Lifesciences Holdings' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.6% of votes cast including abstentions in favor at the meeting held May 26, 2026.
Which companies are in Maravai Lifesciences Holdings' peer group?
The disclosed peer group names 10x Genomics Inc., Azenta, Inc., Bio-Techne Corporation, Cytek Biosciences, Inc. and Fulgent Genetics, Inc., among others.
What is Maravai Lifesciences Holdings' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 93:1, against median employee compensation of $117,383.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Martin
Former Chief Executive Officer
◇◇◇◇◇—◇◇
Carl Hull
Chief Executive Officer and Executive Chairman of the Board
◇—◇◇◇——◇
Peter Leddy
Chief Administrative Officer
◇◇◇◇◇—◇◇
Kevin Herde
Chief Financial Officer
◇—◇◇◇—◇◇
Christine Dolan
Chief Operating Officer, Biologics Safety Testing
◇—◇◇◇—◇◇
Brian Neel
Chief Operating Officer, Nucleic Acid Production
◇◇◇◇◇——— not reconciled
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Carl Hull
Executive Chairman and Former Interim Chief Executive Officer
Departed during or after this year
◇—◇◇———◇
Andrew Burch
President, Nucleic Acid Production
◇◇◇◇——◇◇
Peter Leddy
Chief Administrative Officer
◇◇◇◇——◇◇
Kevin Herde
Chief Financial Officer
◇◇◇◇——◇◇
William Martin
Chief Executive Officer
◇—◇———◇◇
Christine Dolan
General Manager, Cygnus Technologies
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Martin
Chief Executive Officer
◇—◇—◇—◇◇
Andrew Burch
Former President, Nucleic Acid Production
Departed during or after this year
◇◇◇—◇—◇◇
Rebecca Buzzeo
Chief Commercial Officer
◇◇◇—◇——◇
Peter Leddy
Chief Administrative Officer
◇◇◇—◇—◇◇
Kevin Herde
Chief Financial Officer
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernd Brust
Chief Executive Officer
◇—◇◇◇—◇◇
William Martin
Former Chief Executive Officer
Departed during or after this year
◇—◇———◇◇
Raj Asarpota
Chief Financial Officer
◇◇◇◇◇—◇◇
Peter Leddy
Former Chief Administrative Officer
Departed during or after this year
◇—◇—◇—◇◇
Kevin Herde
Former Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Kurt Oreshack
Executive Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Christine Dolan
Executive Vice President and General Manager, Cygnus
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bernd BrustOPTION◇——◇—◇◇
Bernd BrustPSU◇—◇———◇
Bernd BrustRSU◇——◇——◇
Raj AsarpotaOPTION◇——◇—◇◇
Raj AsarpotaRSU◇——◇——◇
Raj AsarpotaPSU◇—◇———◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Raj AsarpotaRSU◇◇——
PSU◇◇——
Option◇—◇6/30/2035
Bernd BrustRSU◇◇——
PSU◇◇——
Option◇—◇6/8/2035
Kevin HerdeRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2033
Option◇—◇1/25/2032
Peter LeddyRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/15/2032
Option◇—◇3/15/2033
Kurt OreshackRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2033
Option◇—◇1/25/2032
Christine DolanRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2033
Option◇—◇1/25/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Bernd Brust
Chief Executive Officer · Employment agreement · citing a 2025 filing
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-solicit period◇
Christine Dolan
Executive Vice President and General Manager, Cygnus · Employment agreement · citing a 2023 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Kevin Herde
Former Chief Financial Officer · Employment agreement · citing a 2023 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Kurt Oreshack
Executive Vice President, General Counsel and Secretary · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance base◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
R. Andrew Eckert
Board chair
◇◇————◇
Susannah Gray
◇◇————◇
John DeFord
◇◇————◇
John De Ford
◇◇————◇
Jessica Hopfield
◇◇————◇
Constantine Mihas
◇◇————◇
Sean Cunningham
◇◇————◇
Murali K. Prahalad
◇◇————◇
Gregory T. Lucier
◇◇————◇
Benjamin Daverman
◇◇————◇
Luke Marker
◇◇————◇
Bernd Brust, William E. Martin III and William Martin served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics Inc. TXG
  • Azenta, Inc. AZTA
  • Bio-Techne Corporation TECH
  • Cytek Biosciences, Inc. CTKB
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health GH
  • Halozyme Therapeutics, Inc. HALO
  • iRythm Technologies symbol not shown
  • Lantheus Holdings, Inc. LNTH
  • Natera, Inc. NTRA
  • Neogen Corporation NEOG
  • Repligen Corporation RGEN
  • Sotera Health Company SHC
  • Tandem Diabetes Care, Inc. TNDM
  • Twist Bioscience Corp. TWST
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 26, 2026=◇◇◇
2024May 22, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022May 18, 2023=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Bernd Brust (Chief Executive Officer), FY2025 total compensation $10,129,708 (base salary $388,863) [exec_comp, SEC accession 0001823239-26-000014, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Maravai Lifesciences Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Maravai Lifesciences Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Maravai Lifesciences Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Maravai Lifesciences Holdings' disclosed peer group is defensible, who names Maravai Lifesciences Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
289 figures on this page: 285 cited to the filing that reported them, 4 calculated from figures it prints.
285 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001823239-26-000046
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001823239-26-000014
    2025 Director Compensation · CHIEF EXECUTIVE OFFICER PAY RATIO · Compensation Discussion and Analysis · EXECUTIVE AND DIRECTOR COMPENSATION · and 2 more sections
  3. 0001823239-25-000065
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-085761
  5. 0001823239-24-000082
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-114058
  7. 0001823239-23-000041
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-108444
  9. 0001193125-25-137478
    EX-10.23
  10. 0001823239-23-000039
    EX-10.25 · EX-10.26
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Maravai Lifesciences Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MRVI (accessed 2026).
Short form: data: Velarion

The Maravai Lifesciences Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Maravai Lifesciences Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Maravai Lifesciences Holdings discloses

The companies named in MRVI's own disclosed peer group.

10x Genomics Inc.Azenta, Inc.Bio-Techne CorporationCytek Biosciences, Inc.Fulgent Genetics, Inc.Guardant HealthHalozyme Therapeutics, Inc.Lantheus Holdings, Inc.Natera, Inc.Neogen CorporationRepligen CorporationSotera Health CompanyTandem Diabetes Care, Inc.Twist Bioscience Corp.Veracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy